Core - Biomarker Development Laboratory (BDL)

作为生物标记表征中心的一部分，生物标记开发实验室 将开发改进的方法来检测DNA甲基化变化，以便及早检测 患上了肺癌。由詹姆斯·赫尔曼博士和王子慧博士领导的多学科 一组研究人员将开发改进的DNA甲基化改变面板，能够 检测循环肿瘤DNA(CtDNA)在血浆中的变化，以确定来源 从肺癌或其他常见恶性肿瘤中提取ctDNA，并继续改进 在甲基化检测方法中，更好地检测存在于 血浆。EDRN生物标记物开发实验室将使用高质量、 前瞻性地收集生物标本以开发高度敏感、特异和 检测肿瘤特异性DNA甲基化的定量方法 血浆中的异常。这些方法将转移到Biomarker参考资料中 实验室将在CLIA环境下进行标准化和性能测试。

As part of a Biomarker Characterization Center, the Biomarker Development Laboratory will develop improved methods to detect DNA methylation changes for the early detection of lung cancer. Led by Dr. James Herman and Dr. Tza-Huei Jeff Wang, a multidisciplinary team of investigators will develop improved panels of DNA methylation alterations able to detect circulating tumor DNA (ctDNA) changes in plasma, to determine the origin of ctDNA from lung cancer or other common malignancies, and to continue improvements in methylation detection methods to better detect the small amounts of ctDNA present in plasma. This EDRN Biomarker Development Laboratory will use high quality, prospectively collected biospecimens to develop highly sensitive, specific and quantitative approaches for the detection of tumor-specific DNA methylation abnormalities in plasma. These methods will be transferred to the Biomarker Reference Laboratory to be standardized and tested for performance in a CLIA setting.